Research on the Interferon Lambda family (IFN-λs, type-III IFNs) has blossomed over the past decade. Unknown until 2003 and initially seen as largely redundant to type-I IFNs, it is increasingly clear that IFN-λs, that include IFN-λ1-4, play an important role in a wide range of conditions through mechanisms that challenge existing paradigms of IFN function.

A meeting entitled, ‘IFN-λ: Disease Impact and Translational Potential,’ will be held at the National Institutes of Health in Bethesda, Maryland on October 25-26, 2018. The meeting is being sponsored by the intramural and extramural divisions of the National Cancer Institute with support from the National Institute of Allergy and Infectious Diseases and several interest groups of NIH. The purpose of the meeting is to promote research on IFN-λs by enhancing interdisciplinary communication and encouraging new collaborations. Presentations will address IFN-λ biology, IFN-λ therapy, genetic association of variants in the IFN-λ region with multiple phenotypes and response to treatment, as well as the role of IFN-λ in hepatitis C virus (HCV) and other infections, hepatic fibrosis and cancer.

There is no registration fee, but pre-registration is required and attendance will be limited to 100 participants.

Presentations by an outstanding group of invited speakers will be augmented by short talks selected from submitted abstracts. A poster session will provide additional opportunities for scientific interactions. The deadline for abstract submissions is September 1, 2018 with notification of disposition by September 14, 2018.

Organizing Committee:

Thomas O’Brien
Division of Cancer Epidemiology and Genetics
National Cancer Institute

Ludmila Prokunina-Olsson
Division of Cancer Epidemiology and Genetics
National Cancer Institute

Howard Young
Center for Cancer Research
National Cancer Institute

Raymond Donnelly
Center for Drug Evaluation and Research
Food and Drug Administration

718 total views, 5 views today